Illustrating risk vs benefit with the tiotropium Respimat inhaler

Patient decision aids present evidence-based estimates of the risks and benefits of a particular treatment. Here, Dr Chris Cates illustrates the benefit of tiotropium in reducing exacerbations in COPD and the increased risk of mortality associated with administration via the Respimat inhaler.

Illustrating risk vs benefit with the tiotropium Respimat inhaler

Add yours ↓
Web design and marketing agency Leamington Spa